The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Autor: | Blackman AL; Department of Pharmacy, Boston Medical Center, Boston, MA, USA.; Department of Pharmacy Practice and Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA., Heil EL; Department of Pharmacy Practice and Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA., Devanathan AS; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA., Pandit NS; Department of Pharmacy Practice and Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Antiviral therapy [Antivir Ther] 2020; Vol. 25 (2), pp. 115-119. |
DOI: | 10.3851/IMP3355 |
Abstrakt: | Background: Pharmacokinetic (PK) changes can affect antiretroviral (ARV) systemic exposure for critically ill patients living with HIV (CI-PLWH). Studies to guide ARV adjustments in this population are limited. Methods: A PK analysis was conducted in a 44-year-old CI-PLWH who presented for a heart and lung transplant on veno-arterial extracorporeal membrane oxygenation (VA ECMO). Home ARV therapy (ART) of co-formulated abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) was continued. ARV serum concentrations were obtained during and after VA ECMO. Two blood levels were drawn at 1 h, for maximum serum concentration (C Results: Area under the concentration-time curve (AUC Conclusions: ART adjustments would not be required for this patient. Additional studies are needed to assess effects of VA ECMO and crushed tube administration of ARVs in CI-PLWH. |
Databáze: | MEDLINE |
Externí odkaz: |